LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: El Typus Melancholicus de Tellenbach como endo-fenotipo de la Depresión Melancólica.

    Widakowich, Christian

    Vertex (Buenos Aires, Argentina)

    2016  Volume XXVII, Issue 125, Page(s) 56–60

    Abstract: The concept of Typus Melancholicus has been proposed by German psychiatrist Hubertus Tellenbach (1914-1994) in 1960 to describe the pre-morbid personality of endogenous or melancholic depression. Thisentity shows distinctive personalitytraits: the order ... ...

    Title translation Typus Melancholicus as endophenotype of melancholic depression.
    Abstract The concept of Typus Melancholicus has been proposed by German psychiatrist Hubertus Tellenbach (1914-1994) in 1960 to describe the pre-morbid personality of endogenous or melancholic depression. Thisentity shows distinctive personalitytraits: the order attachment, strong moral conscience, intolerance ambiguity and hypernomia-heteronomy. Tellenbach uses atypological and phenomenological approach allows the descriptionof styles, ways of being and becoming ill, with a vulnerability to specific situations (moving, pregnancy, career change). Melancholy would settle after the meeting between the Typus Melancholicus with a particular vulnerable situation. This clearly calls into question the classical idea that sees Kraepelinienne endogenous depression as a diseasede termined by heredity and lack of stressors. We propose to describe Tellenbach's concept, and to summarize the more recent empirical researches that valid the Typus Melancholicus as a phenotype for Melancholia.
    Language Spanish
    Publishing date 2016-01
    Publishing country Argentina
    Document type English Abstract ; Journal Article
    ISSN 0327-6139
    ISSN 0327-6139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article: La enfermedad maníaco-depresiva: aspectos psicodinámicos y sintonía afectiva.

    Widakowich, Christian

    Vertex (Buenos Aires, Argentina)

    2015  Volume 26, Issue 119, Page(s) 28–33

    Abstract: In a time when manic-depressive disease became bipolar disorder, and it is conceptualized and treated almost as a fully medical illness, such as epilepsy, we found worth returning to some psychodynamic aspects underlying this condition. Conventionally, ... ...

    Title translation THE MANIC DEPRESSIVE DISEASE: PSYCHODYNAMICS ASPECTS AND AFFECTIVE SYNTONY.
    Abstract In a time when manic-depressive disease became bipolar disorder, and it is conceptualized and treated almost as a fully medical illness, such as epilepsy, we found worth returning to some psychodynamic aspects underlying this condition. Conventionally, we depart from the concept of melancholy, to introduce in a second time, the mania, as a liberating solution of the depression. To Abraham (1912), mania is the liberation from suffering imposed by the reality principle For Freud (1915), mania becomes a leak from the ego face a tyrannical superego (the encounter of ego and the ego ideal). Klein (1934) explains that the mania serves to counter the depressive position and thus avoid the guilt inside of ego. For Racamier (1979), mania is clearly a frantic negation of the anguish and emotional suffering. Today, some authors as Chabot and Husain try to define the manic depression organization, with the help of projective tests. This personality structure would be between psychosis and borderline. An axial element of this structure is the research for an affective symbiosis with each other. These concept, strongly resemble the "syntony", from Bleuler. We trace the evolution of manic depression from a psychodynamic and structural point of view, with particular interesting in the concept of syntony.
    MeSH term(s) Affect ; Bipolar Disorder/psychology ; Humans
    Language Spanish
    Publishing date 2015-01
    Publishing country Argentina
    Document type English Abstract ; Journal Article
    ISSN 0327-6139
    ISSN 0327-6139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: La enfermedad maníaco-depresiva: aspectos psicodinámicos y sintonía afectiva.

    Widakowich, Christian

    Vertex (Buenos Aires, Argentina)

    2014  Volume 25, Issue 117, Page(s) 338–343

    Abstract: In a time when manic-depressive disease became bipolar disorder, and it is conceptualized and treated almost as a fully medical illness, such as epilepsy, we found worth returning to some psychodynamic aspects underlying this condition. Conventionally, ... ...

    Title translation The manic depressive disease: psychodinamic aspects and affective syntony.
    Abstract In a time when manic-depressive disease became bipolar disorder, and it is conceptualized and treated almost as a fully medical illness, such as epilepsy, we found worth returning to some psychodynamic aspects underlying this condition. Conventionally, we depart from the concept of melancholy, to introduce in a second time, the mania, as a liberating solution of the depression. To Abraham, mania is the liberation from suffering imposed by the reality principle For Freud, mania becomes a leak from the ego face a tyrannical superego (the encounter of ego and the ego ideal). Klein explains that the mania serves to counter the depressive position and thus avoid the guilt inside of ego. For Racamier, mania is clearly a frantic negation of the anguish and emotional suffering. Today, some authors as Chabot and Husain try to define the manic depression organization, with the help of projective tests. This personality structure would be between psychosis and borderline. An axial element of this structure is the research for an affective symbiosis with each other. These concept, strongly resemble the "syntony", from Bleuler. We trace the evolution of manic depression from a psychodynamic and structural point of view, with particular interesting in the concept of syntony.
    MeSH term(s) Bipolar Disorder/psychology ; Humans
    Language Spanish
    Publishing date 2014-09
    Publishing country Argentina
    Document type English Abstract ; Journal Article
    ISSN 0327-6139
    ISSN 0327-6139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

    Widakowich, Christian / Dinh, Phuong / de Azambuja, Evandro / Awada, Ahmad / Piccart-Gebhart, Martine

    Anti-cancer agents in medicinal chemistry

    2008  Volume 8, Issue 5, Page(s) 488–496

    Abstract: HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with ... ...

    Abstract HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in metastatic patients, as well as halving the recurrence rate and improving survival in early breast cancer. Even with these impressive results, the reality is that not all patients will benefit form this therapy, and in those who do, resistance to trastuzumab can often develop within 1 year of treatment initiation. Beyond trastuzumab therapy, a "second wave" of monoclonal antibodies and tyrosine kinase inhibitors has emerged. These drugs have variable properties including: 1) dual inhibition against EGFR and HER-2, such as lapatinib, HKI-272 and pertuzumab; 2) anti-angiogenesis such as bevacizumab and pazopanib; 3) anti-mTOR action such as Temsirolimus; and 4) anti-Hsp90 such as 17-AAG. When used in combination with trastuzumab, or with cytotoxic chemotherapy, or as single agents, these new anti-HER-2 strategies bear the potential of arresting the tumorigenesis process. In this article, we present the current strategies in the treatment of breast cancer patients who overexpress HER-2, with particular focus on new tyrosine kinase inhibitors that can be used in combination with or after trastuzumab therapy.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Clinical Trials as Topic ; Female ; Humans ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Trastuzumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2008-04-28
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2217610-X
    ISSN 1871-5206
    ISSN 1871-5206
    DOI 10.2174/187152008784533062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5583: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Review: side effects of approved molecular targeted therapies in solid cancers.

    Widakowich, Christian / de Castro, Gilberto / de Azambuja, Evandro / Dinh, Phuong / Awada, Ahmad

    The oncologist

    2007  Volume 12, Issue 12, Page(s) 1443–1455

    Abstract: Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are ... ...

    Abstract Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.
    MeSH term(s) Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/adverse effects ; Drug Delivery Systems ; Humans ; Neoplasms/drug therapy ; Protein Kinase Inhibitors/adverse effects ; Receptor, Epidermal Growth Factor/antagonists & inhibitors ; Receptor, ErbB-2/antagonists & inhibitors
    Chemical Substances Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2007-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.12-12-1443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Molecular targeted therapies in breast cancer: where are we now?

    Widakowich, Christian / de Azambuja, Evandro / Gil, Thierry / Cardoso, Fatima / Dinh, Phuong / Awada, Ahmad / Piccart-Gebhart, Martine

    The international journal of biochemistry & cell biology

    2007  Volume 39, Issue 7-8, Page(s) 1375–1387

    Abstract: Targeted therapies, in cancer treatment, represent a new generation of drugs that interfere with specific molecular targets (typically proteins) having critical roles to play in tumour growth or progression. The principle of targeted therapy is certainly ...

    Abstract Targeted therapies, in cancer treatment, represent a new generation of drugs that interfere with specific molecular targets (typically proteins) having critical roles to play in tumour growth or progression. The principle of targeted therapy is certainly not new: tamoxifen, a hormonal agent targeted at the estrogen receptor, has been in use for more than 30 years. However, this principle has re-gained significant emphasis with the recent development of new biological agents, such as trastuzumab, which was first approved for the treatment of advanced breast cancer (BC) in 1998. Presently, there are at least three different targeted therapies with well documented activity in advanced BC and all three are now being studied in the adjuvant setting; trastuzumab and bevacizumab are monoclonal antibodies, and lapatinib is a dual inhibitor of HER-1 and HER-2. This paper will review the increasing role of molecular targeted therapies in BC, with a particular focus on those drugs currently being tested in early BC, as well as, on future perspectives.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use ; Bevacizumab ; Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; Female ; Genes, erbB-2/physiology ; Humans ; Quinazolines/therapeutic use ; Receptor, Epidermal Growth Factor/metabolism ; Receptors, Estrogen/antagonists & inhibitors ; Receptors, Estrogen/metabolism ; Tamoxifen/therapeutic use ; Trastuzumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Quinazolines ; Receptors, Estrogen ; Tamoxifen (094ZI81Y45) ; lapatinib (0VUA21238F) ; Bevacizumab (2S9ZZM9Q9V) ; EGFR protein, human (EC 2.7.10.1) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2007
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1228429-4
    ISSN 1878-5875 ; 1357-2725
    ISSN (online) 1878-5875
    ISSN 1357-2725
    DOI 10.1016/j.biocel.2007.04.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 431: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top